

Financial Tear Sheet

Primary IR Contact

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com
(mailto:invest@ctibiopharma.com)

Transfer Agent

Computershare

Mail:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078

Overnight Delivery:
Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States of America

T: 312-588-4187
F: 312-601-4332
www.Computershare.com
(http://www.computershare.com)

Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

Stock Performance: CTIC (Nasdaq)

| | |
|--------------------|-----------------------|
| Exchange | NASDAQ CM (US Dollar) |
| Price | \$5.08 |
| Change (%) | ▲ 0.18 (3.67%) |
| Volume | 5,426,923 |
| 52 Week Low | \$2.45 |
| Market Cap | \$294,542,987 |
| Rolling EPS | -0.66 |
| PE Ratio | 0 |
| Shares Outstanding | 57,980,903 |

Data as of 06/22/18 4:00 p.m. ET



Recent Headlines & Events

Jun 14, 2018 - 7:03 a.m.

CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2354543)

There are currently no events scheduled.

Jun 06, 2018 - 7:01 a.m.

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2353463)

May 21, 2018 - 8:38 p.m.

CTI Biopharma Corporate Presentation (<http://phx.corporate-ir.net/external.file?t=2&item=o8hHt16027g9XhJTr8+weNRYaV9bFc2rMd0Q/AXw4zsGF7Ag1q6UQW1oRa+ipSrxisFQ5niiANNZqJoDdmvApa/iBJZ5V79LpNz1bbUQ9wWqyIGzSqAq8c5ZIS8dCMdnIwieeEB4p4fo8QtUarWk9Q==&cb=636638296115429996>)

Ownership Summary

Shareholders

| | Holders | Value (\$MM) | % O/S | Shares |
|-------------|----------------|---------------------|--------------|---------------|
| Institution | 100 | 152.02 | 67.1 | 38,901,846 |
| Mutual Fund | 38 | 33.91 | 14.2 | 8,254,168 |
| Insider * | 7 | 2.75 | 1.2 | 691,405 |

**Insider values reflect direct beneficial ownership.*

Top Holders

| | Shares Held | % O/S | Share Change | Filing Date |
|--|--------------------|--------------|---------------------|--------------------|
| BVF Partners L.P. | 6,929,690 | 12.0 | -1,666,667 | 03/31/18 |
| Stonepine Capital Management, LLC | 5,141,746 | 8.9 | 3,306,908 | 03/31/18 |
| OrbiMed Advisors, LLC | 5,000,000 | 8.6 | 0 | 03/31/18 |
| New Enterprise Associates (NEA) | 3,750,000 | 6.5 | 3,750,000 | 03/31/18 |
| Franklin Advisers, Inc. | 3,472,300 | 6.0 | 3,472,300 | 03/31/18 |
| The Vanguard Group, Inc. | 2,152,864 | 3.7 | 1,301,983 | 03/31/18 |
| Great Point Partners, LLC | 1,687,020 | 2.9 | 1,687,020 | 03/31/18 |
| Fidelity Management & Research Company | 1,400,000 | 2.4 | 1,400,000 | 03/31/18 |
| NB Public Equity Komplementar ApS | 1,356,635 | 2.3 | 90,000 | 12/31/16 |
| Sphera Funds Management Ltd. | 833,633 | 1.4 | 0 | 03/31/18 |

Data provided by Nasdaq. Minimum 15 minutes delayed.